219 related articles for article (PubMed ID: 27665383)
1. Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study.
Zeiger RS; Schatz M; Dalal AA; Chen W; Sadikova E; Suruki RY; Kawatkar AA; Qian L
J Allergy Clin Immunol Pract; 2017; 5(1):144-153.e8. PubMed ID: 27665383
[TBL] [Abstract][Full Text] [Related]
2. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma.
Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Gossage D; Tran TN
J Allergy Clin Immunol Pract; 2014; 2(6):741-50. PubMed ID: 25439366
[TBL] [Abstract][Full Text] [Related]
3. Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting.
Zeiger RS; Schatz M; Dalal AA; Qian L; Chen W; Ngor EW; Suruki RY; Kawatkar AA
J Allergy Clin Immunol Pract; 2016; 4(1):120-9.e3. PubMed ID: 26439182
[TBL] [Abstract][Full Text] [Related]
4. Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma.
Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Tran TN
J Allergy Clin Immunol Pract; 2017; 5(4):1050-1060.e9. PubMed ID: 28215604
[TBL] [Abstract][Full Text] [Related]
5. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
[TBL] [Abstract][Full Text] [Related]
6. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
7. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.
Price DB; Rigazio A; Campbell JD; Bleecker ER; Corrigan CJ; Thomas M; Wenzel SE; Wilson AM; Small MB; Gopalan G; Ashton VL; Burden A; Hillyer EV; Kerkhof M; Pavord ID
Lancet Respir Med; 2015 Nov; 3(11):849-58. PubMed ID: 26493938
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Outcomes of HEDIS-Defined Asthma Patients with COPD Diagnostic Coding.
Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Tran TN
J Allergy Clin Immunol Pract; 2016; 4(2):273-83.e5. PubMed ID: 26619923
[TBL] [Abstract][Full Text] [Related]
9. Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma.
Papi A; Ryan D; Soriano JB; Chrystyn H; Bjermer L; Rodríguez-Roisin R; Dolovich MB; Harris M; Wood L; Batsiou M; Thornhill SI; Price DB
J Allergy Clin Immunol Pract; 2018; 6(6):1989-1998.e3. PubMed ID: 29627457
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for severe eosinophilic asthma.
Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population.
Kerkhof M; Tran TN; Soriano JB; Golam S; Gibson D; Hillyer EV; Price DB
Thorax; 2018 Feb; 73(2):116-124. PubMed ID: 28918400
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
13. Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease.
Zeiger RS; Tran TN; Butler RK; Schatz M; Li Q; Khatry DB; Martin U; Kawatkar AA; Chen W
J Allergy Clin Immunol Pract; 2018; 6(3):944-954.e5. PubMed ID: 29153881
[TBL] [Abstract][Full Text] [Related]
14. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
15. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
[No Abstract] [Full Text] [Related]
16. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Busse WW; Wenzel SE; Casale TB; FitzGerald JM; Rice MS; Daizadeh N; Deniz Y; Patel N; Harel S; Rowe PJ; Graham NMH; O'Riordan T; Pavord ID
Lancet Respir Med; 2021 Oct; 9(10):1165-1173. PubMed ID: 34181876
[TBL] [Abstract][Full Text] [Related]
17. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
[TBL] [Abstract][Full Text] [Related]
19. Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study.
Vedel-Krogh S; Fallgaard Nielsen S; Lange P; Vestbo J; Nordestgaard BG
Clin Chem; 2017 Apr; 63(4):823-832. PubMed ID: 28209625
[TBL] [Abstract][Full Text] [Related]
20. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
DuBuske L; Newbold P; Wu Y; Trudo F
Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
